Sildenafil citrate therapy for pulmonary arterial hypertension [13]

New England Journal of Medicine

Volumn 354, Issue 10, 2006, Pages 1091-1092

  Izbicki, Gabriel ^a   Rosengarten, Dror ^a   Picard, Elie ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNIPROST; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE;

CLINICAL TRIAL; EXERCISE TOLERANCE; HEMODYNAMICS; HUMAN; LETTER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; NOTE; RANDOMIZED CONTROLLED TRIAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; PATIENT SELECTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33644826152     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053442     Document Type: Letter

References (5)

1. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:81S-88S.
2. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
3. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
4. [Erratum, N Engl J Med 2002;346:1258.]
5. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002;20:1037-49.